EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Low Dose of Dihydroquercetin (DHQ) in Two Genetic Models of Neurodegeneration: Insights from FUS[1-359]-Tg and APPswe/PS1dE9 Paradigms

Ekaterina Lysikova, Kseniia Sitdikova iD, Aigerim Makhambetova, Kirill Chaprov iD, Anna Gorlova, Andrey Kostin, Polina Novikova, Alexei Lyundup, Sholpan Askarova iD, Michail S Kukharsky iD, Alexey Deykin iD, Tatyana Strekalova

Cells · 02.09.2026 · 15 (17) · 1598

DOI: 10.3390/cells15171598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 02.09.2026. Verfasst von Ekaterina Lysikova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Sciences, Medical Research Council, London W12 0HS, UK. Hauptthemen laut MEDLINE: Quercetin, RNA-Binding Protein FUS, Neurodegenerative Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Higher Education and Science of the Republic of Kazakhstan, and the Ministry of Science and Higher Education of RF, HORIZON EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydroquercetin (DHQ), a powerful antioxidant and regulator of cellular metabolism, was proposed for therapy of neurodegenerative disorders. Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) are serious neurodegenerative disorders with oxidative stress as an overlapping feature and unmet therapeutic needs. To date, few studies have explored the efficacy of DHQ in animal models of genetically driven neurodegeneration. Here, APPswe/PS1dE9 (APP/PS1) mice and their wild-type (WT) littermates were orally administered DHQ (0.6 mg/kg/day) for four months, starting at eight months of age. At the age of 12 months, behavioral evaluation was performed, followed by brain staining with Congo red for amyloid plaque scoring and immunohistochemical analysis of GFAP-positive cells for the assessment of astrogliosis. Malondialdehyde (MDA) levels in the prefrontal cortex were studied as a marker of oxidative stress. Second, two-month-old FUS[1-359]-Tg mice, which recapitulate the hallmarks of ALS, received DHQ for 1.5 months and were investigated for general physiological parameters, the onset of paralysis, motor functions, and density of motor neurons in the spinal cord. DHQ-treated APPswe/PS1dE9 mutants displayed a decrease in amyloid plaque density of small size (≤100 μm) in the cortex and thalamus, had normalized MDA levels, improved conditioned taste aversion and Y-maze learning, and ameliorated anxiety measures, whereas their hippocampus-dependent step-down and pellet displacement performance remained impaired. In the second study, DHQ-treated FUS[1-359]-Tg mice showed rescued density of spinal cord neurons, normalized liquid and diet intake, and improved coat state, while the onset of paralysis and motor scores were not significantly ameliorated. Thus, chronic administration of low doses of DHQ exerted neuroprotective effects in both AD and ALS genetic models, which partially translated to reduced manifestations of these diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinRNA-Binding Protein FUSNeurodegenerative DiseasesAnimalsMice, TransgenicDisease Models, AnimalMiceAlzheimer DiseaseOxidative StressBrainPresenilin-1HumansMale

Stichwörter der Autor:innen

APPswe/PS1dE9 miceAlzheimer’s disease (AD)FUS[1-359]-Tg miceamyotrophic lateral sclerosis (ALS)antioxidantsdihydroquercetin

Substanzen

QuercetintaxifolinRNA-Binding Protein FUSPresenilin-1

Autor:innen und Institutionen

  • Laboratory of Medical Sciences, Medical Research Council, London W12 0HS, UK.
  • Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
  • Laboratory of Genetic Technology and Gene Editing for Biomedicine and Veterinary, National Research Belgorod State University, 308015 Belgorod, Russia.
  • Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of Russian Academy of Sciences, 142432 Chernogolovka, Russia.
  • Research and Education Resource Center, Peoples Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
  • Department of Normal Physiology, Sechenov University, 117198 Moscow, Russia.

ORCID-Profile: Kseniia Sitdikova, Kirill Chaprov, Sholpan Askarova, Michail S Kukharsky, Alexey Deykin

Förderung

  • the Ministry of Higher Education and Science of the Republic of Kazakhstan
  • and the Ministry of Science and Higher Education of RF
  • HORIZON EU
  • the Ministry of Science and Higher Education of RF
  • European Union’s Horizon 2020 research and innovation program

Zitieren

APA

Lysikova, E., Sitdikova, K., Makhambetova, A., Chaprov, K., Gorlova, A., Kostin, A., Novikova, P., Lyundup, A., Askarova, S., Kukharsky, M. S., Deykin, A., & Strekalova, T. (2026). Efficacy of Low Dose of Dihydroquercetin (DHQ) in Two Genetic Models of Neurodegeneration: Insights from FUS[1-359]-Tg and APPswe/PS1dE9 Paradigms. Cells, 15(17), 1598. https://doi.org/10.3390/cells15171598

Vancouver

Lysikova E, Sitdikova K, Makhambetova A, Chaprov K, Gorlova A, Kostin A, et al. Efficacy of Low Dose of Dihydroquercetin (DHQ) in Two Genetic Models of Neurodegeneration: Insights from FUS[1-359]-Tg and APPswe/PS1dE9 Paradigms. Cells. 2026;15(17):1598. doi:10.3390/cells15171598

BibTeX
@article{Lysikova2026,
  author = {Lysikova, Ekaterina and Sitdikova, Kseniia and Makhambetova, Aigerim and Chaprov, Kirill and Gorlova, Anna and Kostin, Andrey and Novikova, Polina and Lyundup, Alexei and Askarova, Sholpan and Kukharsky, Michail S and Deykin, Alexey and Strekalova, Tatyana},
  title = {Efficacy of Low Dose of Dihydroquercetin (DHQ) in Two Genetic Models of Neurodegeneration: Insights from FUS[1-359]-Tg and APPswe/PS1dE9 Paradigms},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {17},
  pages = {1598},
  doi = {10.3390/cells15171598}
}
Kostenlos starten →